



XANTHINE OXIDASE INHIBITORS FROM SELECTED
MALAYSIAN MEDICINAL PLANTS AS POTENTIAL
REMEDIES FOR GOUT

BY

SAIFUL MOHAMMAD NIZAM BIN AZMI

A dissertation submitted in fulfilment of the requirement
for the degree of Master of Science
(Biotechnology Engineering)

Kulliyyah of Engineering
International Islamic University
Malaysia

JUNE 2012

ABSTRACT

Xanthine oxidase (XO) is an enzyme that catalyses the metabolism of hypoxanthine and xanthine to uric acid. It is accountable for the medical condition known as gout due to deposition of uric acid in the joints, causing painful inflammation. Inhibition of XO leads to remission in gout. Malaysia houses abundant of medicinal plants, which can be introduced as new natural sources of gout medication and as alternative to synthetic xanthine oxidase inhibitors (XOI), like allopurinol which brings many side effects. The preliminary screening study of different parts of plant from several plant species revealed that aqueous extract of *Carica papaya* L. leaves possess promising XO inhibitory activity at a concentration of 100 µg/ml. Thus, response surface methodology (RSM) from Design Expert® v.6.0.8 was used to study the effects of temperature (°C), time (hour), agitation speed (rpm), and ratio of sample to the solvent (g/ml) on enhancement of XOI production. The analysis of variance (ANOVA) demonstrated that the F-value was 15.07, which implies that the model is significant with low probability value ($p < 0.0001$); having the residuals distributed along a well randomized straight line. Coefficient of determination (R^2) was 93.36%. The p -value of 0.2349 for the lack of fit indicated the model has no lack of fit that further validates the model. Statistical optimization helped in developing the process conditions and the percentage of XO inhibition was enhanced to $88.68 \pm 1.82\%$, obtained at 30°C, 15 hours, 125 rpm and 1g/20ml. The inhibition was less by 5% as compared to allopurinol ($93.69 \pm 0.2\%$). Qualitative analysis on the optimized distilled water extract of *Carica papaya* L. leaves (ODEC) showed the presence of secondary metabolites such as flavonoids, alkaloids, xanthine alkaloids, saponins, anthranol glycosides and terpenoids. Quantitative analysis of ODEC showed the presence of 27.51-33.15% flavonoids, 14.43-16.72% alkaloids and 1.12-1.97% saponins. The ODEC was subjected to reversed-phase flash column chromatography and high performance thin layer chromatography for rapid separation and purification. Fraction EEA1 with R_f value of 0.767 was isolated and demonstrated $95.70 \pm 2.57\%$ of XO inhibition, much higher than allopurinol. Partial identification via HPLC on the ODEC and EEA1 against phenolic acids and flavonoids standards revealed the presence of three phenolic acids and four flavonoids. They were caffeic acid, p -coumaric acid, ferulic acid, myricetin, quercetin, kaempferol and apigenin whereas EEA1 has only quercetin (now denoted as purified compound, PC), which could explain the pharmacological properties of this plant and demonstrate its importance in daily intake especially for gout patient. Quercetin demonstrated competitive mode of inhibition against XO. Antioxidant activities were investigated with BHT, a renowned antioxidant used primarily as food additive as positive control. ODEC and PC scavenged 2, 2-diphenyl-1-picrylhydrazyl (DPPH) activity at an IC_{50} of 2.86 µg/ml and 3.14 µg/ml, respectively. ODEC inhibited β -carotene bleaching at an IC_{50} of 2.13 µg/ml whereas PC at 2.16 µg/ml. Ferric reducing antioxidant power (FRAP) of ODEC was 1146.89 ± 44.24 µmol $FeSO_4 \cdot 7H_2O/g$ dry, 1.8-fold higher than unoptimized extract (UODEC), 1.3-fold higher than PC and 1.5-fold higher than BHT. However, ODEC and PC exhibited minimal anti-diabetic activities. The data grants imperative breakthrough to discover natural XOI from plants and the findings are encouraging to plan clinical studies in hyperuricemic patients, and in the formulation of nutraceuticals or pharmaceuticals, or cosmeceuticals products incorporating natural-based XOI.

ملخص البحث

أوكسيديز الزانثين (XO) هو إنزيم يحفز عملية التمثيل الغذائي للهيپوزانثين والزانثين إلى حمض اليوريك. وهو المسؤول عن حالة طبية تعرف باسم مرض النقرس بسبب ترسب حمض البوليك في المفاصل ، مما يسبب التهاباً مؤلماً. تثبيط أوكسيديز الزانثين (XO) يؤدي إلى الهوادة في مرض النقرس. تزخر معظم المنازل الماليزية بمختلف النباتات الطبية التي يعتبر بعضهاً منها قادراً على تثبيط أنزيم أوكسيديز الزانثين، الذي يمكن تقديمه كمصدر طبيعي جديد لأدوية مرض النقرس و كبدلاً لمثبطات أوكسيديز الزانثيم (XO) الإصطناعية، مثل الوبورينول التي لها آثاراً جانبية عديدة . كشفت دراسة الفرز الأولى لمائتي جزء نباتي من ثلاثين نوعاً مختلفاً من الأصناف النباتية أن المستخلص المائي لأوراق نبات (كارريكا البابايا) يمتلك نشاطاً مثبطاً لإنزيم أوكسيديز الزانثين عند تركيز ١٠٠ ميكروجرام/ مل، لذلك تم استخدام منهجية الإستجابة السطحية (RSM) لدراسة تأثير كلاً من درجة الحرارة (درجة مئوية)، الوقت (ساعة)، سرعة التهيج (دورة في الدقيقة)، و نسبة العينة إلى المذيب (جرام/ مل) على تعزيز إنتاج إنزيم أوكسيديز الزانثين (XO). أظهرت نتائج تحليل التباين (ANOVA) أن قيمة F-value تساوي ١٥,٠٧ والتي تشير إلى أن النموذج ذو أهمية (significant) مع احتمال ضعيف بحوالي ($p < 0,1000$) ، ومخلفات موزعة على طول خط مستقيم بطريقة عشوائية. وكان معامل التحديد (R^2) يساوي القيمة ٣٦,٩٣٪. قيمة عدم وجود التناسب ($p=0,9432$) تشير إلى أن النموذج يُظهر عدم وجود أي تناسب عند التأكد من صحة النموذج. ساعدت عملية التحسين الإحصائية في تطوير ظروف العملية وتعززت نسبة تثبيط أوكسيديز الزانثين (XO) إلى $1,82 \pm 0,88\%$ عند 30 درجة مئوية، 15 ساعة، 125 دورة في الدقيقة، و 1 جرام/ 20 مل. وكان النشاط أقل بنسبة 5% بالمقارنة مع نشاط أوبورينول ($0,2 \pm 93,69\%$). وأظهر التحليل النوعي لمستخلص الماء المقطر الأمثل من أوراق كارريكا البابايا (ODEC) وجود عدة عمليات أيض ثائوية، وبصورة رئيسية ، الفلافونويد ، قلويدات ، قلويدات الزانثين ، الصابونين ، جليكوسيدات الأنتانول و التيربينويدس. وأظهر التحليل الكمي لل ODEC وجود مركبات الفلافونويد ($0,27 \pm 0,33\%$)، قلويدات ($0,14 \pm 0,16\%$) والصابونين ($0,1 \pm 0,97\%$). تعرضت خلاصة الماء المقطر لأوراق نبات كارريكا البابايا (ODEC) إلى عملية كروماتوغرافيا عكس المرحلة لفلاش العمود و كروماتوغرافيا الورقية عالية الأداء للحصول على عملية فصل و تنقية سريعة. الجزء رقم (١) من إيثانول: إيثانول اسيتيت مع قيمة الترددات اللاسلكية $R_f = 0,776$ غُزل و أثبت أن $0,2 \pm 0,95\%$ من تثبيط أنزيم أوكسيديز الزانثين (XO) أعلى بكثير من اللوبورينول. من خلال استخدام تقنية (HPLC) على ODEC و EEA1 ضد معايير الأحماض الفينولية و الفلافونيدات تبين وجود ثلاثة أحماض فينولية و أربعة فلافونيدات. وهي حمض الكافيك ، حمض بي-كوماريك، حمض الفيروليك، مايريسيتين، كويرسيتين، كيمبفيرول، و ابيجينين بينما يحتوي EEA1 على كويريسيتين فقط (تدل على المركب النقي، PC)، والتي يمكن أن تفسر الخصائص الدوائية لهذا النبات وتظهر أهميته في الجرعة اليومية وخاصة بالنسبة لمرضى النقرس. و قد تم دراسة نشاطات مضادات الأكسدة مع بوتيل هيدروكسي تولوين (BHT) ، ومضادات الأكسدة المعروفة تستخدم في المقام الأول كا مضافات غذائية ومراقبات إيجابية. تم كسح و تثبيط نشاط $0,2$ ، 2 ديفيناييل بيكريل هيدرازيل (DPPH) باستخدام (ODEC) و (PC) عند IC_{50} و القيم الناتجة كانت ($86,2$ و $14,3$) ميكروجرام/مل على التوالي. (ODEC) تثبطت عملية التبييض الناتجة عن مادة بيتا كاروتين عند IC_{50} و القيمة الناتجة كانت ($13,2$) ميكروجرام/ مل ، بينما المركب النقي (PC) أعطى قيمة تبلغ ($16,2$) ميكروجرام/ مل. كانت القوة الحديدية لخفض الأكسدة (FRAP) لخلاصة الماء المقطر غير المحسن لأوراق كارريكا البابايا (UODEC) تساوي $11464 \pm 24,44$ ميكروجرام من $FeSO_4 \cdot 7H_2O$ /جرام جاف، والتي تعتبر $8,1$ أضعاف أعلى من مستخلص كارريكا البابايا غير المحسن، و $3,1$ أضعاف أعلى من (PC) ، و $0,1$ أضعاف أعلى من (BHT) . و يملك كلاً من (UODEC) و المركبات النقية (PC) تأثيراً متفوقاً لتثبيط أنزيم أوكسيديز الزانثين (XO). إن البيانات التي تم الحصول عليها من خلال هذه الدراسة ، توفر معلومات هامة لاكتشاف (XOI) جديدة من النباتات الطبيعية و هذه الأكتشافات تشجع على إنتاج منتج دوائي لمكافحة مرض النقرس، فضلاً عن خطة الدراسات السريرية للمرضى الذين يعانون من فرط حمض اليوريك في الدم.

APPROVAL PAGE

I certify that I have supervised and read this study and that in my opinion it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a dissertation for the degree of Master of Science (Biotechnology Engineering).

Parveen Jamal
Supervisor

Azura Amid
Co-Supervisor

I certify that I have read this study and that in my opinion it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a dissertation for the degree of Master of Science (Biotechnology Engineering).

Irwandi Jaswir
Examiner (Internal)

Siddig Ibrahim Abdelwahab
Examiner (External)

This dissertation was submitted to the Department of Biotechnology Engineering and is accepted as a fulfilment of the requirement for the degree of Master of Science (Biotechnology Engineering).

Md. Zahangir Alam
Head, Department of
Biotechnology Engineering

This dissertation was submitted to the Kulliyah of Engineering and is accepted as a fulfilment of the requirement for the degree of Master of Science (Biotechnology Engineering).

Amir Akramin Shafie
Dean, Kulliyah of Engineering

DECLARATION

I hereby declare that this dissertation is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Saiful Mohammad Azmi bin Azmi

Signature

Date

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION
OF FAIR USE OF UNPUBLISHED RESEARCH**

Copyright © 2012 by International Islamic University Malaysia. All rights reserved.

**XANTHINE OXIDASE INHIBITORS FROM SELECTED
MALAYSIAN MEDICINAL PLANTS AS POTENTIAL REMEDIES FOR
GOUT**

I hereby affirm that the International Islamic University Malaysia (IIUM) hold all rights in the copyright of this work and henceforth any reproduction or use in any form or by means whatsoever is prohibited without the written consent of IIUM. No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder.

Affirmed by Saiful Mohammad Nizam bin Azmi.

.....
Signature

.....
Date

ACKNOWLEDGMENTS

In The Name of Allah, the Most Beneficent, the Most Merciful

Alhamdulillah, praised be to Allah (SWT) who taught by the Pen, He taught man that which he knew not, as under His kind blessings, I am able to successfully complete my dissertation in order to fulfil the requirements for the degree of Master of Science (Biotechnology Engineering) from International Islamic University Malaysia (IIUM). Undoubtedly, I have gained a lot of new experience, exposure and knowledge in completing this research.

My deepest and heartiest appreciation goes to my supervisors, Associate Professor Dr. Parveen Jamal and Associate Professor Dr. Azura Amid for their continuous support, patience, encouragement and supervision. Surely, this research will not be a successful one without their thoughtfulness and a helping hand whenever I need scholarly assistance and guidance.

I am grateful to IIUM Research Management Center (RMC) for approving the research grant (Endowment Fund Type A) and to the Ministry of Higher Education (MOHE) for providing the scholarship that enabled me to further my Master degree. Not to forget, I am thankful to the Director of International Institute for Halal Research and Training (INHART), IIUM, Associate Professor Dr. Hamzah Mohd Salleh for lending me a calm and quiet place to write my dissertation.

I am also indebted to my parents, Haji Azmi bin Abdul Rahman and Hajah Sepiah binti Mat Rohim, and siblings as their endless love and moral support have eased my journey to complete this study. To my colleagues, Sr. Nur Izzah Ismail, Br. Tamrin Nuge, Br. Mohd Azmir Ariffin, Br. Wan Mohd Fadzli Wan Nawawi, Br. Zulkarnain Idris, Sr. Anumsima Ahmad Barkat, Sr. Liyana Yahya, Sr. Afraha Baiti, Sr. Ruqayyah Tijani, Br. Farid Moukit, Sr. Alawiyah, Sr. Ricca Rahman, Sr. Wan Dalila Wan Chik and Br. Dedi Noviendri, thank you for your co-operation and kind friendship. My credit also goes to other lecturers who were indirectly shares their knowledge and expertise. Finally, I wish to thank the Head of Department and staff of Department of Biotechnology Engineering for their assistantship in completing this valuable research.

I would like to apologize if in any circumstances, I have offended anybody during the completion of this research as well as for any shortcomings appeared in this dissertation. I have put on my very best effort to ensure that this dissertation and the research as a whole is a successful one. Thank you. May Allah bestow His bless upon us all.

TABLE OF CONTENTS

Abstract.....	ii
Abstract in Arabic.....	iii
Approval Page.....	iv
Declaration.....	v
Copyright Page.....	vi
Acknowledgments.....	vii
List of Tables.....	xii
List of Figures.....	xv
List of Abbreviations.....	xx
CHAPTER ONE: INTRODUCTION.....	1
1.1 Background of the Study.....	1
1.2 Problem Statement and Its Significance.....	3
1.3 Research Objectives.....	5
1.4 Research Methodology.....	6
1.5 Scope of Research.....	8
1.6 Dissertation Organization.....	9
CHAPTER TWO: LITERATURE REVIEW.....	10
2.1 Introduction.....	10
2.2 Xanthine Oxidase (XO)	11
2.2.1 Protein Structure of XO.....	12
2.2.2 Active Site of XO.....	14
2.2.3 Mechanism of Action of XO.....	16
2.2.4 Mechanism of Uric Acid Production.....	16
2.3 Hyperuricemia.....	18
2.3.1 Complications of Hyperuricemia.....	21
2.3.1.1 Gout.....	21
2.3.1.2 Urolithiasis.....	24
2.3.1.3 Reactive Oxygen Species (ROS) Production.....	25
2.3.2 Antihyperuricemic Therapy.....	26
2.4 Xanthine Oxidase Inhibitors (XOI)	28
2.4.1 Allopurinol.....	29
2.4.2 Febuxostat.....	31
2.5 Medicinal Plants.....	32
2.6 Phenolic Compounds from Medicinal Plants as XOI.....	35
2.6.1 Phenolic Acids.....	37
2.6.1.1 Biosynthesis of Phenolic Acids.....	39
2.6.2 Flavonoids.....	40
2.6.2.1 Biosynthesis of Flavonoids.....	42
2.6.2.2 Biological Effects of Flavonoids.....	44
2.7 Solid-Liquid Extraction.....	46
2.7.1 Solvent Systems for Extraction.....	47
2.7.2 Process Conditions for Extraction.....	49

2.7.2.1	Extraction Temperature (°C)	50
2.7.2.2	Extraction Time (hour)	51
2.7.2.3	Agitation Speed in revolution per minute (rpm)	52
2.7.2.4	Ratio of Sample to the Solvent (g/ml)	52
2.8	Statistical Optimization.....	52
2.8.1	Response Surface Methodology (RSM).....	53
2.8.2	Central Composite Design (CCD).....	54
2.9	Chromatographic Fractionation of XO Compound.....	54
2.9.1	Isolation and Purification of XO Compound.....	55
2.9.2	Partial Identification of XO Compound.....	56
2.9.2.1	Qualitative and Quantitative Analysis of XO Compounds.....	57
2.9.2.2	High Performance Liquid Chromatography (HPLC).....	58
2.10	Mode of Enzyme Activity Inhibition.....	59
2.11	Biochemical Assays for Several Biological Activities.....	59
2.11.1	Measurements of Antioxidant Activities.....	60
2.11.1.1	DPPH Radical Scavenging Activity Assay.....	60
2.11.1.2	Inhibition of β -Carotene Bleaching.....	61
2.11.1.3	Ferric Reducing/Antioxidant Power (FRAP) Assay....	62
2.11.2	Measurements of Anti-Diabetic Activities	62
2.11.2.1	β -Glucosidase Inhibition Assay.....	62
2.11.2.2	α -Amylase Inhibition Assay by CNPG3 Method.....	63
2.12	Summary.....	63

CHAPTER THREE: MATERIALS AND METHODS..... 65

3.1	Introduction.....	65
3.2	Experimental Materials.....	65
3.2.1	Collection of Plant Materials and Preparation of Sample.....	67
3.2.2	Chemicals and Reagents.....	67
3.2.2	Equipments and Instruments.....	67
3.3	Experimental Methods.....	72
3.3.1	Preparation of Crude Extracts	72
3.3.2	Determination of XO Inhibitory Activity	72
3.3.2.1	Xanthine Oxidase Inhibitory Activity Assay.....	73
3.3.3	Optimization of Process Conditions for Extraction.....	74
3.3.3.1	Experimental Design for Optimization.....	75
3.3.3.2	Statistical Analysis.....	76
3.3.4	Qualitative Analysis of Potential Phytoconstituents as XO.....	77
3.3.4.1	Detection of Phenol.....	77
3.3.4.1.1	Ferric Chloride Test.....	77
3.3.4.2	Detection of Flavonoids	77
3.3.4.2.1	Alkaline Reagent Test.....	77
3.3.4.2.2	Zinc Hydrochloric Acid Reduction Test.....	78
3.3.4.3	Detection of Alkaloids	78
3.3.4.3.1	Mayer's Test.....	78
3.3.4.3.2	Wagner's Test.....	78
3.3.4.3.3	Dragendorff's Test.....	79
3.3.4.3.4	Ehrlich's Test.....	79
3.3.4.3.5	Vitali-Morin Test.....	79

3.3.4.3.6	Ammonia Reaction Test.....	80
3.3.4.4	Detection of Saponins.....	80
3.3.4.4.1	Emulsion Formation Test.....	80
3.3.4.4.2	FrothTest.....	80
3.3.4.5	Detection of Glycosides.....	80
3.3.4.5.1	Modified Borntrager's Test.....	81
3.3.4.5.2	Legal's Test.....	81
3.3.4.6	Detection of Diterpenes.....	81
3.3.4.6.1	Copper Acetate Test.....	81
3.3.4.6.2	Sulphuric Acid Reaction Test.....	81
3.3.4.6.3	Antimony Trichloride Reaction Test.....	82
3.3.4.7	Detection of Carbohydrates.....	82
3.3.4.7.1	Benedict's Test.....	82
3.3.4.7.2	Fehling's Test.....	82
3.3.4.8	Detection of Phytosterols.....	83
3.3.4.8.1	Liebermann Burchard's Test.....	83
3.3.4.8.2	Tshugajeu Test.....	83
3.3.4.9	Detection of Fixed Oils and Fats.....	83
3.3.4.9.1	Stain Test.....	83
3.3.4.10	Detection of Proteins and Amino Acids.....	84
3.3.4.10.1	Xanthoproteic Test.....	84
3.3.4.10.2	Ninhydrin Test.....	84
3.3.4.10.3	Biuret Test.....	84
3.3.5	Quantitative Analysis of Potential Phytoconstituents as XOI....	84
3.3.5.1	Estimation of Flavonoids.....	84
3.3.5.2	Estimation of Alkaloids.....	85
3.3.5.3	Estimation of Saponins.....	85
3.3.6	Isolation and Purification of XOI Compound.....	86
3.3.7	Partial Identification of Phenolic as XOI by HPLC.....	87
3.3.8	Determination of Mode of Enzyme (XO) Activity Inhibition....	88
3.3.9	Determination of Antioxidant Activities.....	88
3.3.9.1	DPPH Radical-Scavenging Activity.....	88
3.3.9.2	Inhibition of β -Carotene Bleaching	89
3.3.9.3	Ferric Reducing/Antioxidant Power (FRAP) Assay....	90
3.3.10	Determination of Anti-Diabetic Activities.....	91
3.3.10.1	β -Glucosidase Inhibition Assay	91
3.3.10.2	α -Amylase Inhibition Assay by CNPG3 Method	92
3.4	Summary.....	92

CHAPTER FOUR: RESULTS AND DISCUSSION..... 94

4.1	Introduction.....	94
4.2	Screening Of Potential Plant Materials and Extraction Solvent for XOI Production.....	95
4.2.1	Screening of Plant Materials for XO Inhibitory Activity.....	95
4.2.2	Selection of Extraction Solvent for Optimization of Process Conditions.....	101
4.3	Optimization of Process Conditions For Extraction.....	103
4.3.1	Statistical Experimental Analysis.....	103
4.3.2	Model Prediction and Fitting.....	106

4.3.3	Analysis using Response Surface Methodology.....	108
4.3.4	Validation of the Optimized Extraction Parameters.....	118
4.3.5	Comparison of XO Inhibition between Allopurinol and Optimized Extract.....	119
4.3.6	IC ₅₀ Evaluation on XO Inhibitory Activity.....	121
4.4	Qualitative and Quantitative Analysis of Potential XOI Compound.....	123
4.4.1	Preliminary Identification of Potential Compounds as XOI.....	123
4.4.2	Quantitative Analysis of <i>Carica papaya</i> Leaves for their Phytoconstituents.....	126
4.5	Purification of XOI Compound from <i>Carica papaya</i> L. Leaves	126
4.5.1	The Efficacy of TLC-RPFCC-HPTLC for the Purification of XOI.....	126
4.6	Partial Characterization of XOI Compound by HPLC.....	131
4.6.1	HPLC Separation of Flavonoids and Phenolic Acids.....	132
4.7	Mode of Enzyme Activity Inhibition.....	136
4.8	Evaluation of Antioxidant Activities.....	140
4.8.1	Scavenging Activity of DPPH Radical.....	140
4.8.2	Inhibition of β -Carotene Bleaching.....	142
4.8.3	Ferric Reducing Activity.....	144
4.9	Evaluation of Anti-Diabetic Activities.....	146
4.9.1	Inhibition of β -Glucosidase Activity.....	146
4.9.2	Inhibition of α -Amylase Activity.....	149
4.10	Summary.....	151

CHAPTER FIVE: CONCLUSION AND RECOMMENDATION..... 153

5.1	Conclusion.....	153
5.2	Recommendation.....	156

BIBLIOGRAPHY..... 158

APPENDIX A.....	186
APPENDIX B.....	188
APPENDIX C.....	189
APPENDIX D.....	190
APPENDIX E.....	193
APPENDIX F.....	200

LIST OF TABLES

<u>Table No.</u>		<u>Page No.</u>
2.1	Annual incidence of gouty arthritis according to the serum urate concentration.	19
2.2	Common drugs used in the management of gout.	27
2.3	Classification of families of phenolic compounds in plants	37
3.1	List of botanical plants under evaluation, their scientific names, common names, local names, reported medicinal benefits and different parts evaluated.	68
3.2	Coded and actual levels of the design factors.	74
3.3	Experimental design using CCD for optimization showing in coded and actual values.	76
4.1	Evaluation of XO inhibitory activity by Malaysian medicinal plants extracts in three different solvent systems.	96
4.2	Arrangement of experimental runs from central composite design showing coded and actual values of four independent variables along with the experimental and predicted values for XO inhibitory activity.	105
4.3	Statistical analysis of variance of independent variables for optimization the process conditions for extraction of XO.	107
4.4	Experimental and predicted values for %XO inhibitory activity according to the suggested process conditions.	118
4.5	XO inhibitory activity of allopurinol and optimized distilled water extract of <i>Carica papaya</i> L. leaves at various concentrations.	120
4.6	Qualitative analysis on the optimized distilled water extract of <i>Carica papaya</i> L. leaves.	124
4.7	R _f values of the separated constituents from the selected eluents via preparative silica-coated TLC plates.	128

4.8	Retention time of the phenolic compounds under investigation (in the standard mixture, compounds detected in the optimized extract and phenolic compound in the purified sample).	134
4.9	V_{\max} and K_m of quercetin on XO inhibition.	136
4.10	DPPH radical-scavenging activities of BHT, distilled water extracts of <i>Carica papaya</i> L. leaves (unoptimized and optimized) and quercetin at various concentrations.	140
4.11	Inhibition of β -carotene bleaching of BHT, distilled water extracts of <i>Carica papaya</i> L. leaves (unoptimized and optimized) and quercetin at various concentrations.	143
4.12	β -glucosidase inhibition activity of distilled water extracts of <i>Carica papaya</i> L. leaves (unoptimized and optimized) and quercetin at various concentrations	147
4.13	Inhibition of α -amylase activity of distilled water extracts of <i>Carica papaya</i> L. leaves (unoptimized and optimized) and quercetin at various concentrations.	149

LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
1.1	Overview of process methodology employed in the process of obtaining XOI compound from the selected medicinal plant and its disease-prevention efficacy.	6
2.1	Enzymatic process catalyzed by XO. $O_2^{\cdot-}$ is superoxide radical anion and H_2O_2 is hydrogen peroxide.	11
2.2	Crystal structure of bovine milk XO from Protein Data Bank (Entry code: 1FIQ). FE/S is iron-sulfur cofactors, FAD is flavin adenine dinucleotide cofactor and Mo-pt is molybdopterin cofactor.	13
2.3	Amino acid residues that contribute in the catalytic reaction at the XO active site. Glu is glutamic acid, Phe is phenylalanine, Arg is arginine and Gln is glutamine.	15
2.4	Mechanism of uric acid production initiated by hydrogen abstraction and followed by carbanion attack on Mo=O.	17
2.5	Schematic diagram of purine degradation pathway. GMP is guanosine monophosphates, AMP is adenosine monophosphates and IMP is inosine 5'-monophosphate. IMP is the precursor of both AMP and GMP.	20
2.6	Formation of microscopic crystals of sodium urate in the joint area leads to acute gouty arthritis.	21
2.7	Role of uric acid in the inflammatory response of gout. Phagocytosis of uric acid crystals by neutrophils generates harmful reactive oxygen metabolites and the release of hydrolytic enzyme causes acute inflammation.	22
2.8	Chronic tophaceous gouty arthritis.	23
2.9	The formation of ROS induced by XO during oxidative half reaction in uric acid production pathway.	25
2.10	Allopurinol that is a structural isomer of hypoxanthine (natural purine base). Allopurinol is clinically used XOI that has served as a dominant uric acid-lowering agent in the past three decades for the treatment of gout.	29

2.11	Chemical structures of hydroxybenzoic acids. (a) Gallic acid, (b) <i>p</i> -hydroxybenzoic acid, (c) Protocatechuic acid, (d) Vanillic acid, (e) Syringic acid, and (f) Salicylic acid.	28
2.12	Chemical structures of hydroxycinnamic acids. (a) <i>p</i> -coumaric acid, (b) Caffeic acid, (c) Ferulic acid, and (d) Sinapic acid.	29
2.13	Generic structure of flavonoid molecule.	41
2.14	Generic structure of major classes of flavonoids. (a) Flavone, (b) Flavonol, (c) Flavanone, (d) Flavanol, and (e) Anthocyanidins.	42
2.15	Biosynthetic pathways leading to flavonoid-derived products in plants. Common names for different flavonoid classes are capitalized. Major biosynthetic routes for which enzymes have been characterized on a molecular level are shown. Refer to List of Abbreviations for the enzyme abbreviations.	43
2.16	Chemical structures of various flavonoids that have been evaluated to be effective as inhibitors of XO in vitro. Class of flavones: (a) Apigenin, (b) Luteolin (R=H) and Luteolin-7-O-glucoside (R=Glc), class of flavonols: (c) Kaempferol, (d) Quercetin, and class of flavanones: (e) Eriodictyol and (f) Naringenin.	45
2.17	Reaction between DPPH [•] and antioxidant to form DPPH	60
2.18	β -Carotene bleaching assay. (a) Proposed mechanism of lipid peroxidation; (b) Formation of adducts from β -Carotene and antioxidant with lipid peroxide radical.	61
2.19	Formation of (Fe ²⁺ -TPTZ) complex from (Fe ³⁺ -TPTZ) complex by antioxidant	62
3.1	Overview of the experimental studies to identify XO1 compound from Malaysian medicinal plant.	66
3.2	Ferrous sulfate (FeSO ₄) standard curve	90
4.1	Statistical comparison on nine plant materials extracted using (a) distilled water, (b) aqueous-methanol, and (c) absolute ethanol. Values are presented as means \pm standard deviation (SD) of triplicate measurements.	99
4.2	Response surface and contour plot showing the effect of extraction time and extraction temperature on XO inhibition activity with other variables at zero level. (a) 2-D contour plot response surface. (b) 3-D plot response surface.	110

4.3	Response surface and contour plot showing the effect of agitation speed and extraction temperature on XO inhibition activity with other variables at zero level. (a) 2-D contour plot response surface. (b) 3-D plot response surface.	111
4.4	Response surface and contour plot showing the effect of ratio of 1 g of sample to solvent and extraction temperature on XO inhibition activity with other variables at zero level. (a) 2-D contour plot response surface. (b) 3-D plot response surface.	113
4.5	Response surface and contour plot showing the effect of agitation speed and extraction time on XO inhibition activity with other variables at zero level. (a) 2-D contour plot response surface. (b) 3-D plot response surface.	114
4.6	Response surface and contour plot showing the effect of ratio of 1 g of sample to solvent and extraction time on XO inhibition activity with other variables at zero level. (a) 2-D contour plot response surface. (b) 3-D plot response surface.	116
4.7	Response surface and contour plot showing the effect of ratio of 1 g of sample to solvent and agitation speed on XO inhibition activity with other variables at zero level. (a) 2-D contour plot response surface. (b) 3-D plot response surface.	117
4.8	XO inhibitory activity (%) as a function of allopurinol and optimized extract concentrations. Results are expressed as means \pm SD ($n = 3$). IC ₅₀ value for allopurinol (3.74 μ g/ml) is lower than the optimized sample (4.33 μ g/ml).	122
4.9	Some of the secondary metabolites detected in the optimized crude extract of <i>Carica papaya</i> leaves using distilled water as the extraction solvent; (a) flavonoids, (b) alkaloids, (c) xanthine alkaloids, (d) saponins, and (e) anthranol glycosides, which may have contributed on the total XO inhibitory activity.	125
4.10	Separated constituents observed under short wave UV light, utilizing Methanol-Hexane (MH) as the mobile phase and silica as the stationary phase. The R _f values (X100) of the separated constituents for the 9:1 ratio TLC plate are shown.	127
4.11	Separated constituents observed under short wave UV light, utilizing Ethanol-Ethyl Acetate (EEA) as the mobile phase and silica as the stationary phase. The R _f values (X100) of the separated constituents for the 9:1 ratio TLC plate are shown.	127

4.12	Separated constituents observed under short wave UV light, utilizing Methanol-Ethanol as the mobile phase and silica as the stationary phase. The R_f values (X100) of the separated constituents for the 9:1 ratio TLC plate are shown.	128
4.13	The process employed in the isolation and purification of XO1 compound. (a) Reversed-phase flash column chromatography with the flow rate fixed at 5 ml/min. (b) High performance thin layer chromatography to enhance the separation of the bioactive compounds of interest.	129
4.14	Inhibition of XO by optimized distilled water extract of <i>Carica papaya</i> L. leaves (ODEC), allopurinol (synthetic XO1) and all ten fractions recovered from HPTLC at a final concentration of 100 $\mu\text{g/ml}$. Each value is represented as mean \pm S.D. from triplicate measurement.	130
4.15	HPLC profiles of (a) standard mixtures of phenolic compounds containing 10 phenolic acids and 4 flavonoids; (b) compounds detected in the extract produced at optimum extraction conditions; (c) phenolic compound in the purified sample. Peak identification: 1, gallic acid; 2, 4-hydroxybenzoic acid; 3, 4-hydroxyphenyl acetic acid; 4, vanillic acid; 5, caffeic acid; 6, <i>p</i> -coumaric acid; 7, ferulic acid; 8, sinapic acid; 9, syringic acid; 10, <i>o</i> -coumaric acid; 11, myricetin; 12, quercetin; 13, kaempferol; 14, apigenin; UK1, unknown 1 and UK2, unknown 2.	133
4.16	Michaelis-Menten plot of (a) a control as a function of substrate; (b) purified compound from obtained from ODEC (PC, quercetin) as a function of substrate.	137
4.17	Lineweaver-Burk plot for competitive inhibition of quercetin against XO with V_{max} value of $6.22 \pm 0.34 \mu\text{M/min}$ and K_m value of $21.38 \pm 2.81 \mu\text{M}$.	138
4.18	Radical scavenging activity on DPPH as a function of BHT, unoptimized distilled water extract of <i>Carica papaya</i> L. leaves (UODEC), optimized distilled water extract of <i>Carica papaya</i> L. leaves (ODEC) and purified compound recovered from ODEC (PC, Quercetin) concentrations. BHT was used as positive control. Data are expressed as means \pm SD ($n = 3$).	142
4.19	Inhibition of β -carotene bleaching as a function of BHT, unoptimized distilled water extract of <i>Carica papaya</i> L. leaves (UODEC), optimized distilled water extract of <i>Carica papaya</i> L. leaves (ODEC) and purified compound recovered from ODEC (PC, Quercetin) concentrations. BHT was used as positive control. Data are expressed as means \pm SD ($n = 3$).	144

4.20	Ferric reducing activity based on FRAP assay of BHT, unoptimized distilled water extract of <i>Carica papaya</i> L. leaves (UODEC), optimized distilled water extract of <i>Carica papaya</i> L. leaves (ODEC) and purified compound recovered from ODEC (PC, Quercetin). BHT was used as positive control. Data are expressed as means \pm SD ($n = 3$).	145
4.21	Inhibition of β -glucosidase activity as a function of unoptimized distilled water extract of <i>Carica papaya</i> L. leaves (UODEC), optimized distilled water extract of <i>Carica papaya</i> L. leaves (ODEC) and purified compound recovered from ODEC (PC, Quercetin) concentrations. Data are expressed as means \pm SD ($n = 3$).	148
4.22	Inhibition of α -amylase activity as a function of unoptimized distilled water extract of <i>Carica papaya</i> L. leaves (UODEC), optimized distilled water extract of <i>Carica papaya</i> L. leaves (ODEC) and purified compound recovered from ODEC (PC, Quercetin) concentrations. Data are expressed as means \pm SD ($n = 3$).	150

LIST OF ABBREVIATIONS

2Fe - 2S	Two distinct iron-sulphur
4CL	Coumaroyl-CoA-ligase
AC	Acetic acid in chloroform
ACN	Acetonitrile
AlCl ₃	Alcoholic ferric chloride
AMP	Adenosine monophosphates
ANOVA	Analysis of variance
Aq-A	Aqueous acetic acid
Arg	Arginine
BAN	Anthocyanidin reductase
BAW	n-butanol : acetic acid : water
BEW	n-butanol : ethanol : water
BHT	Butylated hydroxytoluene
BMA	Benzene : methanol : acetic acid
BN	n-butanol : ammonium hydroxide
C4H	Cinnamate-4-hydroxylase
CBG	Cytosolic β -glucosidase
CH ₂ Cl ₂	Dichloromethane
CHI	Chalcone isomerase
CHR	Chalcone reductase
CHS	Chalcone synthase
CCD	Central composite design
CPa-1	<i>Carica papaya</i> L. leaves
CPa-5	<i>Carica papaya</i> L. unripe fruit peels
CSa-1	<i>Cucumis sativus</i> L. ripe fruit peels
CSa-2	<i>Cucumis sativus</i> L. seeds
CV	Coefficient of variation
DAD	Diode array detection
DFR	Dihydroglavonol-4-reductase
dH ₂ O	Distilled water
DiEt	Diethyl ether
DMID	7,2'-dihydroxy-4'-methoxyisoflavonol dehydratase
DMSO	Dimethylsulfoxide
DPPH	2,2-diphenyl-1-picrylhydrazyl
EAB	Ethyl acetate in benzene
Eq.	Equation
ESI	Electrospray ionization
EtAc	Ethyl acetate
EtOH	Ethanol
F3'H	Flavonoid 3'-hydroxylase
F3'5'H	Flavonoid 3'5'-hydroxylase
FAD	Flavin adenine dinucleotide
Fe (TPTZ) ₂ (II)	Ferrous tripyridyltriazine
Fe (TPTZ) ₂ (III)	Ferric tripyridyltriazine

FeCl ₃	Ferric chloride
FHT	Flavonone 3- β -hydroxylase
FLS	Flavonols synthase
FNS I/II	Flavone synthase
FRAP	Ferric reducing antioxidant power
Gln	Glutamine
Glu	Glutamic acid
GMa-1	<i>Garcinia mangostana</i> L. leaves
GMa-2	<i>Garcinia mangostana</i> L. ripe fruit peels
GMP	Guanosine monophosphates
H ₂ SO ₄	Sulphuric acid
HCl	Hydrochloric acid
HGPRT	Hypoxanthine – guanine phosphoribosyltransferase
HOCl	Hypochlorous acid
HPLC	High performance liquid chromatography
HPTLC	High Performance thin layer chromatography
Hun-2	<i>Hylocereus undatus</i> (Haw.) Britton & Rose ripe fruit peels
I ² H	Isoflavone 2-hydroxylase
IFR	Isoflavone reductase
IFS	Isoflavone synthase
IIUM	International Islamic University Malaysia
IMP	Inosine 5'-monophosphates
IOMT	Isoflavone <i>O</i> -methyltransferase
K ₂ HPO ₄	Di-potassium hydrogen phosphates
K ₃ Fe(CN) ₆	Potassium ferricyanide
KH ₂ PO ₄	Potassium di-hydrogen phosphates
KOH	Potassium hydroxide
LAR	Leucoanthocyanidin reductase
LC	Liquid chromatography
LDOX (ANS)	Leucoanthocyanidin dioxygenase (anthocyanidin synthase)
LPH	Lactase - phlorizin hydrolase
LPO	Lipid peroxidation
MCi-4	<i>Morinda citrifolia</i> L. leaves
MeOH	Methanol
Mo	Molybdenum
Mo-pt	Molybdopterin cofactor
MS	Mass spectrometry
MSP-1	<i>Mentha spicata</i> L. leaves
NADH	Nicotinamide adenine dinucleotide
NADPH	Nicotinamide adenine dinucleotide phosphate
NaOH	Sodium hydroxide
NAP3	National Agriculture Policy 3
NSAIDs	Non-steroidal anti-inflammatory drugs
ODEC	Distilled water extract of <i>Carica papaya</i> L. leaves
OMT	<i>O</i> -methyltransferase
PAL	Phenylalanine ammonialyase
PC	Purified compound, quercetin
PDB	Protein Data Bank
Phe	Phenylalanine

PhOH	Phosphoric acid : water
PRPP	5-phosphoribosyl- α -pyrophosphates
R _f	Retardation factor
ROS	Reactive oxygen species
RPFCC	Reversed-phase flash column chromatography
rpm	Revolution per minute
RSM	Response surface methodology
RT	Rhamnosyl transferase
SD	Standard deviation
SGTL1	Sodium-dependent glucose transporter
SJS	Steven-Johnsons syndrome
STS	Stilbene synthase
TENS	Toxic epidermal necrolysis syndrome
TLC	Thin layer chromatography
TPTZ	2, 4, 6-tripyridyl-S-triazine
UGT	UDP-glucose : flavonoid glycosyl transferase
UK	United Kingdom
UODEC	Unoptimized distilled water extract of <i>Carica papaya</i> L. leaves
USA	United States of America
UV/VIS	Ultra violet/visible
VAD	Valoneic acid dilactone
VR	Vestitone reductase
WHO	World Health Organization
XO	Xanthine oxidase
XOI	Xanthine oxidase inhibitor

CHAPTER ONE

INTRODUCTION

1.1 BACKGROUND OF THE STUDY

Uric acid is a product of purine metabolism generated during the enzymatic degradation of hypoxanthine and xanthine, catalyzed by an enzyme named xanthine oxidase (XO) (Ramallo et al., 2006; Wang et al., 2008). Elevated concentrations of uric acid in the blood stream created a metabolic arthritis disease called gout. Gout affects a substantial proportion of the adult population. It is the most common form of arthritis in men over the age of 40. Women are less commonly affected but the prevalence may be increased among postmenopausal women (Choi and Curhan, 2007). Gout is common in prosperous and affluent societies due to a diet rich in proteins, fat and alcohol (Choi and Curhan, 2004a; Trivieri et al., 1999). Factors like inherited enzyme deficiencies, obesity, decrease renal function and hypertension also contribute to the elevated concentrations of uric acid (Wright and Pinto, 2003). It is believed that either by increasing the excretion of uric acid or reducing the uric acid production helps to reduce the risk of gout (Umamaheswari et al., 2007).

To date, the treatment of gout entails the use of therapeutic agents such as xanthine oxidase inhibitors (XOI) by blocking the biosynthesis of uric acid from purine in the body (Unno et al., 2004). In the process of blocking the uric acid production, inhibition of XO causes an increase in hypoxanthine and xanthine, which are converted to purine ribotides adenosine and guanosine monophosphates. The increased level of these ribotides causes feedback inhibition of amidophosphoribosyl transferase, the first and rate-limiting enzyme of purine biosynthesis (Borges et al.,

2002). Allopurinol (naturally occurring purine in the body) is one of the few clinically used XOIs (Bieber and Terkeltaub, 2004; Wortmann, 2005). It is reported that allopurinol (i.e. Lopurin, Zurinol, and Zyloprim) inhibits XO and slows the uric acid production rate in the blood and urine (Fields et al., 1996). Allopurinol does not alleviate acute attacks of gout but is useful in preventing recurrence. It is the drug of choice for long-term prophylaxis and is the best medicine for people who have kidney problems caused by uric acid (Fuchs et al., 1999).

However, there are many adverse reactions associated with allopurinol (Kong et al., 2001; Wallach, 1998), ranging from mild skin allergy (i.e. skin rashes, stomach upsets, hives, itching, fever, nausea and muscle pain) to a concerted allopurinol hypersensitivity syndrome, which can cause death (Kong et al., 2000; Pacher et al., 2006; Umpie´rrez et al., 1998). Thus, the problems of using allopurinol imperatively required to be solved by any suitable alternative means such as medicinal plants.

Malaysia is a tropical country, which houses more than 12,000 species of flowering plants. Thus, it is expected that they have well diverse chemical structures from their secondary metabolite and chemical diversity. Some plant-based bioactive compounds such as polyphenols (Costantino et al., 1992), flavonoids (Chang et al., 1993; Cotelle et al., 1996; Selloum et al., 2001), coumarins (Chang and Chiang, 1995), ellagic acid, valoneic acid dilactone (VAD) (Unno et al., 2004), xanthones and beta carbolines have been reported to be potent XOI. In 2005, Malaysian government spent an estimated of RM 8 billion on herbal products and is expected to increase by 20% annually (BiotechCorp, 2010). Thus, a search for substitutes from the plant origin as alternatives to allopurinol for the treatment of gout is highly warranted.

There are numerous studies on XOI compound or compound that have anti-gout properties using medicinal plants. Many of these bioactive compounds were

initially examined for other medicinal benefits such as antioxidant, anticancer, antimicrobial, anti-diabetic, anti-inflammatory and anti-analgesic (Foyet et al., 2011; Goyal et al., 2010; Jung et al., 2006; Kaur et al., 2010; Singh et al., 2010; Soncini et al., 2011; Sulaiman et al., 2011; Wan Norhana et al., 2009). Different methods of extraction and process conditions were used to extract the desired compound. Therefore, optimization study by means of statistical experimental design is vital to determine the optimum conditions needed to yield high production of XOI compound, especially important for scaling-up. Isolation, purification and identification of bioactive compounds allow the formulation, development and commercialization of natural-based products (i.e. cosmeceuticals, nutraceuticals and pharmaceuticals).

This study aims to discover scientific basis for the reputed efficacy of Malaysian plants to inhibit XO. We expect to obtain natural XOI, which will be an alternative to the available treatment of gout and other inflammatory-related diseases.

1.2 PROBLEM STATEMENT AND ITS SIGNIFICANCE

XO plays a key physiological role in the hydroxylation of hypoxanthine and xanthine to uric acid (Ramallo et al., 2006; Wang et al., 2008). Increase in uric acid or decrease in its excretion is normally referred as hyperuricemia (Vázquez-Mellado et al., 2004), which is identified when uric acid concentration is ≥ 7 mg/dl for men and ≥ 6 mg/dl for women (Nakagawa et al., 2006; Schlesinger and Schumacher, 2002). XO also plays an important role in various forms of ischemic injuries, tissue and vascular injuries, inflammatory diseases and chronic heart failure (Pacher et al., 2006).

The prototypical of allopurinol (4-hydroxypyrazolo [3, 4-d] pyrimidine) as XOI has been the cornerstone of the clinical management of gout and conditions